drugset / Trial / NCT02450838
Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)
Phase 1
Completed
20 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Dengue viruses are mosquito-borne flaviviruses. Each year, dengue viruses infect millions of people throughout the tropics and subtropics. This study will evaluate the safety, tolerability, and immunogenicity of a tetravalent recombinant subunit dengue vaccine (V180) in healthy adults who previously received a live-attenuated tetravalent dengue vaccine (TV003 or TV005).
Timeline
- Start
- 2015-04
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | V180 | Vaccine | — | Intramuscular |
| Background | Aluminum hydroxide | Unknown | — | Intramuscular |